Study shows ability of Prostascint to predict prostate cancer deaths:
This article was originally published in Clinica
In what could boost the profile of Prostascint, eight-year outcomes data from a 341-patient study has found that the imaging agent can predict the likelihood of prostate cancer-related deaths. The study, which was presented at last month's American Urological association, in Anaheim, California, found that prostate cancer-specific deaths were 10 times higher in patients that showed central abdominal uptake (CAU) of the agent, which is indicative of metastatic activity. Manufacturers of the agent, Princeton, New Jersey-based Cytogen, commented that the data "reinforces the value of information obtained from Prostascint scans to assist in selection of appropriate therapy". In January of this year, Prostascint was included in the US National Comprehensive Cancer Network (NCCN) clinical practise guidelines for recurrent prostate cancer.